Making the case for the case report – informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor treated chronic myeloid leukemia patients

"Making the case for the case report – informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor treated chronic myeloid leukemia patients." Leukemia & Lymphoma, 63(7), pp. 1522–1523

Disclosures

NJL is a final year medical student at the University of Toronto.

JHL is a Professor of Medicine at Princess Margaret Cancer Center and has/had received research funding and served on advisory boards for Novartis, BMS, Pfizer, Takeda.